[go: up one dir, main page]

Schmid et al., 1974 - Google Patents

Antineoplastic and toxic effects of Acinetobacter and Pseudomonas glutaminase-asparaginases

Schmid et al., 1974

View HTML
Document ID
7673796606343387236
Author
Schmid F
Roberts J
Publication year
Publication venue
Cancer Chemother Rep

External Links

Snippet

The toxicity of highly purified glutaminase-asparaginases from Acinetobacter glutaminasificans (AGA) and Pseudomonas aureofaciens (PGA) was studied in C3H/HeJ, CD1, and BDF, mice. Daily injections of 250 IU/kg of AGA or 125 IU/kg of PGA in lactate …
Continue reading at books.google.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay

Similar Documents

Publication Publication Date Title
Schmid et al. Antineoplastic and toxic effects of Acinetobacter and Pseudomonas glutaminase-asparaginases
Zahavi et al. β-thromboglobulin-a specific marker of in-vivo platelet release reaction
Morantz et al. Macrophages in experimental and human brain tumors: part 2: studies of the macrophage content of human brain tumors
Krown et al. Phase I trials of poly (I, C) complexes in advanced cancer
Taylor Jr et al. Generation of chemotactic activity in rabbit serum by plasminogen-streptokinase mixtures
Hill et al. Response to highly purified L-asparaginase during therapy of acute leukemia
Laszlo et al. Phase I study of pharmacological and immunological effects of human lymphoblastoid interferon given to patients with cancer
Sone Role of alveolar macrophages in pulmonary neoplasias
Youssef et al. Release of platelet factor 4 by adenosine diphosphate and other platelet-aggregating agents
Urba et al. Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine
Cheung et al. Adherence of neutrophils to hemodialysis membranes: Role of complement receptors
US5068223A (en) Hydrophobic peptide esters and amides
Rossi et al. Symptomatic treatment of recurrent malignant pleural effusions with intrapleurally administered Corynebacterium parvum: clinical response is not associated with evidence of enhancement of local cellular-mediated immunity
Ginsburg et al. Poly-L-arginine and an N-formylated chemotactic peptide act synergistically with lectins and calcium ionophore to induce intense chemiluminescence and superoxide production in human blood leukocytes: Modulation by metabolic inhibitors, sugars, and polyelectrolytes
Daar et al. Demonstration with monoclonal antibodies of an unusual mononuclear cell infiltrate and loss of normal epithelial membrane antigens in human breast carcinomas
US5304474A (en) Hydrophobic peptide esters and amides
Krane et al. Treatment of metastatic renal cell carcinoma with autolymphocyte therapy: Low toxicity outpatient approach to adoptive immunotherapy without use of in vivo interleukin-2
Holcenberg et al. Phase I study of succinylated Acinetobacter L-glutaminase-L-asparaginase
Heiskala et al. Characteristics of Soluble Tumour‐Derived Proteins That Inhibit Natural Killer Activity
AU4401200A (en) Use of n-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients
EP1028745B1 (en) Low-dose interferon immunotherapy
Minton et al. The effect of Corynebacterium parvum on the humoral and cellular immune systems in patients with breast cancer
Merrill et al. Regulation of natural killer cell cytotoxicity by prostaglandin E in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases part 2. Effect of Exogenous PGE1 on spontaneous and interferon-induced natural killer
Barna et al. Combination therapy with a synthetic peptide of C-reactive protein and interleukin 2: augmented survival and eradication of pulmonary metastases
Reynard The regulation of complement activity by pharmacologic agents